Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease (TriAL21)

Alzheimer Disease Clinical Trial

Official title: Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease

Status Recruiting

Clinical Trial Summary

TriAL21 study is an interventional, open, one arm, prospective, national and single center study. A total of 200 patients with Down syndrome, aged 35 years and over, without diagnosis of Alzheimer's disease will be enrolled into the study. Participating centre is Institut Jérôme Lejeune; outpatient's clinic dedicated to treating patients with cognitive deficiencies of genetic origin including patients with Down syndrome.

Clinical Trial Description

The aim of the study is to describe and follow a cohort of patients with Down syndrome without diagnosis of Alzheimer's disease at inclusion, in order to identify factors influencing the age of onset of the disease. The total study duration will be approximately 4 years. - Inclusion period : 2 years - Follow-up period per patient : 2 years Patients will be then followed during 10 years for routine medical follow-up. In case of Alzheimer's disease onset during this period, all data regarding diagnosis of AD will be collected for the study. Data about dementia evolution and mortality in case of AD diagnosis during the study will also be collected during this follow-up period. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Down Syndrome
• Syndrome

• NCT number: NCT03901261
• Study type: Interventional
• Source: Institut Jerome Lejeune
• Contact: Anne-Sophie REBILLAT, MD, PhD
• Phone: +33 1 56 58 63 00
• Email: annesophie.rebillat@institutlejeune.org
• Status: Recruiting
• Phase: N/A
• Start date: April 26, 2019
• Completion date: March 31, 2023